2018 International Congress » Clinical Trials and Therapy in Movement Disorders

1:45pm-3:15pm

A case of early onset parkinsonism caused by PLA2G6 gene mutation

L. Chen, S. Xu (Guangdong, China)

1:45pm-3:15pm

A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia

W. Jost, A. Schramm, M. Müngersdorf, A. Stenner, P. Schwingenschuh, P. Maisonobe, M. Koch, B. Haslinger (Wolfach, Germany)

1:45pm-3:15pm

A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

1:45pm-3:15pm

A Preliminary Study of Cinnamomum verum on Anxiety, Locomotor Activity and Emotionality Behaviour in Wistar Albino Rats

N. Ahmed (Aligarh, India)

1:45pm-3:15pm

Advanced Parkinson’s disease Diagnosis and Treatment Trends in Israel – Sub-Analysis of the OBSERVE-PD Multi-Country, Cross-Sectional Study

R. Djaldetti, S. Hassin-Baer, M. Anca-Herschkovitsch, R. Gross, R. Cohen, H. Banayan, K. Onuk, T. Gurevich (Petah Tikva, Israel)

1:45pm-3:15pm

Alleviation of freezing of gait in patients with Parkinson’s disease by high-frequency rTMS over SMA is associated with normalization of brain connectivity patterns

T.M. Mi, S. Garg, F. Ba, T. Wu, P.P. Liang, L.L. Gao, K.C. Li, P. Chan, M. McKeown (Beijing, China)

1:45pm-3:15pm

Ankle proprioception and postural instability in Parkinson’s disease

H. Teasdale, E. Preston, W. Spratford, G. Waddington (Bruce, Australia)

1:45pm-3:15pm

Background: Transcranial magnetic stimulation (rTMS) may influence the progression of PD

J. Málly (Sopron, Hungary)

1:45pm-3:15pm

Bipolar directional DBS in VIM-stimulated patients

J. Steffen, P. Reker, F. Mennicken, T. Dembek, H. Dafsari, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm

Botulinum toxin in Essential Hand Tremor – A Randomized Double-Blind Placebo-Controlled study with Customized Injection Approach

S. Mittal, D. Machado, D. Richardson, D. Dubey, B. Jabbari (Bangalore, India)

1:45pm-3:15pm

Clinical study on the correlation between Parkinson’s somatosensory evoked potentials and STN-DBS parameters

Z. Jing, Y. Xiaoxue, G. Shuzhao, S. Chunli, L. Zhanhua, (Dalian, China)

1:45pm-3:15pm

Comparison of virtual-reality-gaming and activity-based gait and balance training on gait, balance and quality of life in patients with Parkinson’s disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile-Ife, Nigeria)

1:45pm-3:15pm

Deep brain stimulation (DBS) for dyskinetic cerebral palsy: A pilot study

S. Duma, N. Mahant, A. Ha, S. Kim, A. Phu, K. Stewart, M-C. Waugh, N. Wolfe, D. Russell, B. Owler, M. Krause, V. Fung (Westmead, Australia)

1:45pm-3:15pm

Design and Status of the BIIB054 SPARK Trial

Parkinson Study Group, A. Siderowf (NY, USA)

1:45pm-3:15pm

Development of evidence-based clinical practice guideline (CPG) of complementary and alternative medicine (CAM) for Parkinson’s disease (PD)

K.H. Cho, S.W. Kwon, S.H. Lee, T.H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm

Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study

J. Cedarbaum, K. Evans, M. Yang, J. Xiao (Cambridge, MA, USA)

1:45pm-3:15pm

Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease

C. Kutz, L. Adams, E. Moncheski (Colorado Springs, CO, USA)

1:45pm-3:15pm

Efficacy of zonisamide on motor symptoms in dementia with Lewy bodies: A post-hoc analysis of a phase 3 study

H. Maruyama, M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, K. Kosaka (Tokyo, Japan)

1:45pm-3:15pm

Feasibility and Efficacy of Brainstem Modulation Therapy for the Management of Parkinson’s Disease

K. Ade, A. Podlewska, T. Pellet-Higgins, S. Banducci, M. Bodani, M. Sakel, D. Wilkinson (Raleigh, NC, USA)

1:45pm-3:15pm

Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

1:45pm-3:15pm

Improvements of tremor control and life quality of refractory essential tremor patients after MR-guided focused ultrasound thalamotomy – A Taiwan experience

H.C. Lai, K. Tsai, W.C. Chang, T. Taira, C.Y. Wei (Changhua County, Taiwan)

1:45pm-3:15pm

Intraoperative local field potential recordings from deep brain stimulation electrodes help predict efficacy of subthalamic nucleus stimulation in patients with Parkinson’s disease

C. Chen, M. Liu, H. Chan, P. Tu, C. Lu, P. Brown (Taoyuan City, Taiwan)

1:45pm-3:15pm

INTREPID: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

1:45pm-3:15pm

Levodopa effect on non-motor symptoms in late stage Parkinson’s disease

K. Rosqvist, P. Odin, P. Hagell, S. Iwarsson, M. Nilsson, A. Storch (Lund, Sweden)

1:45pm-3:15pm

Linking neuroplastic effects to behavioral changes after balance training in Parkinson’s disease: a study protocol of a randomized controlled trial

E. Franzén, H. Johansson, M. Freidle, U. Ekman, E. Schalling, A. Lebedev, M. Lövdén, S. Holmin, P. Svenningsson, M. Hagströmer (Huddinge, Sweden)

1:45pm-3:15pm

Low-Fat Versus Ketogenic Diet In Parkinson’s Disease: A Pilot Randomized Controlled Trial

M. Phillips, D. Murtagh, L. Gilbertson, F. Asztely, C. Lynch (Hamilton, New Zealand)

1:45pm-3:15pm

Neuroprotective role of Tinospora cordifolia in MPTP induced Parkinsonian mouse model

S. Singh, H. Birla, S. Rai, W. Zahra, S. Singh (Varanasi, India)

1:45pm-3:15pm

Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis

T. Dam, L. Zhang, I. Qureshi, M. Grundman, G. Tirucherai, C. Bechtold, M. Ahlijanian, L. Golbe, L. Honig, S. Isaacson, M. Grossman, N. McFarland, I. Litvan, D. Geldmacher, T. Xie, Y. Bordelon, P. Tuite, P. O’Suilleabhain, T. Zesiewicz, B. Han, A. Boxer (Cambridge, MA, USA)

1:45pm-3:15pm

PASSPORT, An Ongoing Phase 2 Study in Patients with PSP– Baseline Characteristics

T. Dam, A. Boxer, L. Golbe, G. Höglinger, H. Morris, I. Litvan, J.C. Corvol, A. Lang, C. Bechtold, I. Qureshi, M. Grundman, B. Han, J. O'Gorman, T. Olsson, S. Budd Haeberlein (Cambridge, MA, USA)

1:45pm-3:15pm

PPMI driven sample size estimation for clinical trials in Parkinson’s disease

K. Marek, J. Seibyl, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, K. Kieburtz, C. Tanner, L. Chahine, A. Siderowf, T. Simuni (New Haven, CT, USA)

1:45pm-3:15pm

Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

1:45pm-3:15pm

Relationship between non-motor symptom symptoms and clinical symptoms in Parkinson’s disease using “Non-Motor Symptom assessment scale for Parkinson’s disease”

T. Matsubara, K. Suzuki, H. Fujita, M. Matsubara, A. Numao, H. Sakuramoto, Y. Watanabe, T. Kadowaki, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm

Safinamide in Parkinson’s disease

G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

1:45pm-3:15pm

Single limb stance test performance – Difference between tremor dominant and akinetic rigid dominant parkinson’s disease – A pilot study

S. Durairaj, A. Christina, V. Mathew, M. Gowri (Vellore, India)

1:45pm-3:15pm

Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial

W. Meissner, A. Pavy-Le Traon, A. Foubert-Samier, M. Galitzky, B. Laurens, U. Sabatini, S. Schmidhuber, D. Winter, G. Galabova, G. Staffler, A. Schneeberger, A. Kutzelnigg, O. Rascol (Bordeaux Cedex, France)

1:45pm-3:15pm

STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease

J. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm

The effects of Nordic walking on gait functions in people with Parkinson’s disease: A long-term pilot study

M. Mak, I. Wong-Yu (Hong Kong, Hong Kong)

1:45pm-3:15pm

The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a Novel Primary Efficacy Outcome in Patients with Pantothenate Kinase-Associated Neurodegeneration

F. Greblikas, M. Escolar, T. Klopstock, R. Marshall, B. Perez, S. Tuller, A. Videnovic (San Diego, CA, USA)

1:45pm-3:15pm

The PDSAFE falls prevention programe for people with Parkinson’s: A multicentre randomised controlled trial

A. Ashburn, R. Pickering, L. Rochester, H. Roberts, C. Ballinger, S. Hulbert, I. Marian, C. Fitton, E. McIntosh, V. Goodwin, A. Nieuwboer, S. Lamb, K. Chivers Seymour (Southampton, United Kingdom)

1:45pm-3:15pm

The Research of the Structural Changes of Cerebellar Tissue in Tremor-type Parkinson’s Disease Based on DKI

T. Siyu, T. Dan, X. xiaoyan, Q. Jin, H. Xiushuang (Dalian, China)

1:45pm-3:15pm

Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models

M. Lee, E. Newbold, S. Papapetropoulos (Cambridge, MA, USA)

1:45pm-3:15pm

Zonisamide improves parkinsonism in DLB patients: A randomized phase 3 trial

M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, M. Tagawa, K. Kosaka (Kodaira, Japan)